[
1. Organization WH. Obesity and overweight. 2018.
]Search in Google Scholar
[
2. Fox A, Feng W, Asal V. What is driving global obesity trends? Globalization or “modernization”? Global Health 2019;15:32.
]Search in Google Scholar
[
3. NCD Risk Factor Collaboration (NCD-RisC) Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet 2016;387:1377-96.10.1016/S0140-6736(16)30054-X
]Search in Google Scholar
[
4. Narkiewicz K. Obesity and hypertension–the issue is more complex than we thought. Nephrol Dial Transplant. 2006; 21:264–267.10.1093/ndt/gfi290
]Search in Google Scholar
[
5. Crump C, Sundquist J, Winkleby MA, Sundquist K. Interactive effects of physical fitness and body mass index on the risk of hypertension. JAMA Intern Med. 2016; 176:210–216.10.1001/jamainternmed.2015.7444
]Search in Google Scholar
[
6. Juonala M, Magnussen CG, Berenson GS, Venn A, Burns TL, Sabin MA, Srinivasan SR, Daniels SR, Davis PH, Chen W, et al. Childhood adiposity, adult adiposity, and cardiovascular risk factors. N Engl J Med. 2011; 365:1876–1885.10.1056/NEJMoa1010112
]Search in Google Scholar
[
7. World Health Organization. Waist circumference and waist-hip ratio: report of a WHO expert consultation, Geneva, 8-11 December 2011.
]Search in Google Scholar
[
8. Wofford MR, Anderson DC, Jr, Brown CA, et al. Antihypertensive effect of alpha- and beta-adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens 2001;14:694-8.10.1016/S0895-7061(01)01293-6
]Search in Google Scholar
[
9. Lambert EA, Esler MD, Schlaich MP, et al. Obesity-Associated Organ Damage and Sympathetic Nervous Activity. Hypertension 2019;73:1150-9.10.1161/HYPERTENSIONAHA.118.1167631067200
]Search in Google Scholar
[
10. Gentile CL, Orr JS, Davy BM, et al. Modest weight gain is associated with sympathetic neural activation in nonobese humans. Am J Physiol Regul Integr Comp Physiol 2007;292:R1834-8.10.1152/ajpregu.00876.200617218435
]Search in Google Scholar
[
11. Vaz M, Jennings G, Turner A, et al. Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects. Circulation 1997;96:3423-9.10.1161/01.CIR.96.10.3423
]Search in Google Scholar
[
12. Dewan NA, Nieto FJ, Somers VK. Intermittent hypoxemia and OSA: implications for comorbidities. Chest 2015;147:266-74.10.1378/chest.14-0500428508025560865
]Search in Google Scholar
[
13. Cabandugama PK, Gardner MJ, Sowers JR. The Renin Angiotensin Aldosterone System in Obesity and Hypertension: Roles in the Cardiorenal Metabolic Syndrome. Med Clin North Am 2017;101:129-37.10.1016/j.mcna.2016.08.009512554227884224
]Search in Google Scholar
[
14. Schütten MT, Houben AJ, de Leeuw PW, et al. The Link Between Adipose Tissue Renin-Angiotensin-Aldosterone System Signaling and Obesity-Associated Hypertension. Physiology (Bethesda) 2017;32:197-209.10.1152/physiol.00037.2016
]Search in Google Scholar
[
15. Yiannikouris F, Karounos M, Charnigo R, et al. Adipocyte-specific deficiency of angiotensinogen decreases plasma angiotensinogen concentration and systolic blood pressure in mice. Am J Physiol Regul Integr Comp Physiol 2012;302:R244-51.10.1152/ajpregu.00323.2011
]Search in Google Scholar
[
16. Jeon JH, Kim KY, Kim JH, et al. A novel adipokine CTRP1 stimulates aldosterone production. FASEB J 2008;22:1502-11.10.1096/fj.07-9412com
]Search in Google Scholar
[
17. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A 2003;100: 14211-6.10.1073/pnas.2336140100
]Search in Google Scholar
[
18. Grassi G, Seravalle G, Dell’Oro R, et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003;21:1761-9.10.1097/00004872-200309000-00027
]Search in Google Scholar
[
19. Dorresteijn JA, Schrover IM, Visseren FL, et al. Differential effects of renin-angiotensin-aldosterone system inhibition, sympathoinhibition and diuretic therapy on endothelial function and blood pressure in obesity-related hypertension: a double-blind, placebo-controlled cross-over trial. J Hypertens 2013;31:393-403.10.1097/HJH.0b013e32835b6c02
]Search in Google Scholar
[
20. Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015;386:2059-68.10.1016/S0140-6736(15)00257-3
]Search in Google Scholar
[
21. Dwyer TM, Banks SA, Alonso-Galicia M, et al. Distribution of renal medullary hyaluronan in lean and obese rabbits. Kidney Int 2000;58:721-9.10.1046/j.1523-1755.2000.00218.x10916095
]Search in Google Scholar
[
22. Kambham N, Markowitz GS, Valeri AM, et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001;59:1498-509.10.1046/j.1523-1755.2001.0590041498.x11260414
]Search in Google Scholar
[
23. Kotsis V, Stabouli S, Papakatsika S, et al. Mechanisms of obesity-induced hypertension. Hypertens Res 2010;33:386-93.10.1038/hr.2010.920442753
]Search in Google Scholar
[
24. Hall ME, do Carmo JM, da Silva AA, et al. Obesity, hypertension, and chronic kidney disease. Int J Nephrol Renovasc Dis 2014;7:75-88.10.2147/IJNRD.S39739393370824600241
]Search in Google Scholar
[
25. Savoia C, Volpe M, Alonzo A, Rossi C, Rubattu S. Natriuretic peptides and cardiovascular damage in the metabolic syndrome: molecular mechanisms and clinical implications. Clin Sci (Lond) 2010;118:231–240.10.1042/CS2009020419886866
]Search in Google Scholar
[
26. Bordicchia M, Liu D, Amri EZ, Ailhaud G, Dessi-Fulgheri P, Zhang C, Takahashi N, Sarzani R, Collins S. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest. 2012;122:1022–1036.10.1172/JCI59701328722422307324
]Search in Google Scholar
[
27. Zois NE, Bartels ED, Hunter I, Kousholt BS, Olsen LH, Goetze JP. Natriuretic peptides in cardiometabolic regulation and disease. Nat Rev Cardiol. 2014;11: 403–412.10.1038/nrcardio.2014.6424820868
]Search in Google Scholar
[
28. Hall JE, Brands MW, Dixon WN, Smith MJ., Jr Obesity-induced hypertension. Renal function and systemic hemodynamics. Hypertension. 1993;22:292–299.10.1161/01.HYP.22.3.292
]Search in Google Scholar
[
29. Wildman RP, Mackey RH, Bostom A, Thompson T, Sutton-Tyrrell K. Measures of obesity are associated with vascular stiffness in young and older adults. Hypertension. 2003;42:468–473.10.1161/01.HYP.0000090360.78539.CD12953016
]Search in Google Scholar
[
30. Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology. 2003;144:2195-2200.10.1210/en.2003-028512746274
]Search in Google Scholar
[
31. Grassi G, Seravalle G, Cattaneo BM, Bolla G, Lafranchi A, Colombo M, Giannattasio C, Brunani A, Cavagnini F, Mancia G. Sympathetic activation in obese normotensive subjects. Hypertension 1995; 25: 560-563.10.1161/01.HYP.25.4.560
]Search in Google Scholar
[
32. Hall JE, Crook ED, Jones DW, Wolford MR, Dubbert PM. Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci 2002; 324: 127-137.10.1097/00000441-200209000-0000312240710
]Search in Google Scholar
[
33. Kambham N, Markowitz GS, Valeri AM, D’Agati VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001; 59: 1498-1509.10.1046/j.1523-1755.2001.0590041498.x11260414
]Search in Google Scholar
[
34. Deji N, Kume S, Araki S, Soumura M, Sugimoto T, Isshiki K, Chin-Kanasaki M, Chin-Kanasaki M, Sakaguchi M, Koya D, Haneda M, Kashiwagi A, Uzu T. Structural and functional changes in the kidneys of high-fat diet-induced obese mice. Am J Physiol Renal Physiol 2009; 296: F118–F126.10.1152/ajprenal.00110.200818971213
]Search in Google Scholar
[
35. Després JP. Body fat distribution and risk of cardiovascular disease: an update. Circulation 2012;126:1301-13.10.1161/CIRCULATIONAHA.111.06726422949540
]Search in Google Scholar
[
36. Hall ME, do Carmo JM, da Silva AA, et al. Obesity, hypertension, and chronic kidney disease. Int J Nephrol Renovasc Dis 2014;7:75-88.10.2147/IJNRD.S39739393370824600241
]Search in Google Scholar
[
37. DeFronzo RA, Cooke CR, Andres R, et al. The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J Clin Invest 1975;55:845-55.10.1172/JCI1079963018221120786
]Search in Google Scholar
[
38. Muniyappa R, Sowers JR. Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord 2013;14:5-12.10.1007/s11154-012-9229-1359411523306778
]Search in Google Scholar
[
39. Hall JE. Hyperinsulinemia: a link between obesity and hypertension? Kidney Int 1993; 43: 1402–1417.
]Search in Google Scholar
[
40. Creager MA, Liang CS, Coffman JD. Beta adrenergic-mediated vasodilator response to insulin in the human forearm. Am Soc Pharm Exper Ther 1985; 235: 709-714.
]Search in Google Scholar
[
41. Kuo JJ, Jones OB, Hall JE. Inhibition of NO synthesis enhances chronic cardiovascular and renal actions of leptin. Hypertension 2001; 37: 670-676.10.1161/01.HYP.37.2.670
]Search in Google Scholar
[
42. Knudson JD, Payne GA, Borbouse L, Tune JD. Leptin and mechanisms of endothelial dysfunction and cardiovascular disease. Curr Hypertens Rep 2008; 10: 434-439.10.1007/s11906-008-0082-218959828
]Search in Google Scholar
[
43. Korda M, Kubant R, Patton S, Malinski T. Leptin-induced endothelial dysfunction in obesity. Am J Physiol Heart Circ Physiol 2008; 295: H1514-H1521.10.1152/ajpheart.00479.2008259350718689498
]Search in Google Scholar
[
44. Lundberg JM, Pernow J, Franco-Cereceda A, Rudehill A. Effects of antihypertensive drugs on sympathetic vascular control in relation to NPY. J Cardiovasc Pharmacol 1987; 10 (Suppl 12): S51-S68.10.1097/00005344-198710012-00008
]Search in Google Scholar
[
45. Guillod-Maximin E, Roy AF, Vacher CM, Aubourg A, Bailleux V, Lossignol A, Penicaud L, Parquet M, Taonis M. Adiponectin receptors are expressed in hypothalamus and colocalized with POMC and NPY in rodent arcuate neurons. J Endocrinol 2009; 200: 93-105.10.1677/JOE-08-034818971219
]Search in Google Scholar
[
46. Saruta T. Mechanism of glucocorticoid-induced hypertension. Hypertens Res 1996; 19: 1–8.10.1291/hypres.19.18829818
]Search in Google Scholar
[
47. Whitworth JA, Schyvens CG, Zhang Y, Mangos GJ, Kelly JJ. Glucocorticoid-induced hypertension: from mouse to man. Clin Exp Pharmacol Physiol 2001; 28: 993-996.10.1046/j.1440-1681.2001.03584.x11903301
]Search in Google Scholar
[
48. Bentley-Lewis R, Adler GK, Perlstein T, Seely EW, Hopkins PN, Williams GH, Garg R. Body mass index predicts aldosterone production in normotensive adults on a high-salt diet. J Clin Endocrinol Metab 2007; 92:4472-4475.10.1210/jc.2007-1088442858417726083
]Search in Google Scholar
[
49. Goodfriend TL, Kelley DE, Goodpaster BH, Winters SJ. Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes Res 1999; 7:355-362.10.1002/j.1550-8528.1999.tb00418.x10440591
]Search in Google Scholar
[
50. Williams JS, Williams GH. 50 anniversary of aldosterone. J Clin Endocrinol Metab 2003; 88:2364-2372.10.1210/jc.2003-03049012788829
]Search in Google Scholar
[
51. Lai L, Feng X, Liu D, Chen J, Zhang Y, Niu B, Gu Y, Cai H. Dietary salt modulates the sodium chloride cotransporter expression likely through an aldosterone-mediated WNK4-ERK1/2 signaling pathway. Pflugers Arch 2012; 463:477-485.10.1007/s00424-011-1062-y22200850
]Search in Google Scholar
[
52. Chiga M, Rai T, Yang SS, Ohta A, Takizawa T, Sasaki S, Uchida S. Dietary salt regulates the phosphorylation of OSR1/SPAK kinases and the sodium chloride cotransporter through aldosterone. Kidney Int 2008; 74:1403-1409.10.1038/ki.2008.45118800028
]Search in Google Scholar
[
53. Engeli S, Böhnke J, Gorzelniak K, Janke J, Schling P, Bader M, Luft FC, Sharma AM. Weight loss and the reninangiotensin-aldosterone system. Hypertension 2005; 45:356-362.10.1161/01.HYP.0000154361.47683.d315630041
]Search in Google Scholar
[
54. Engeli S, Sharma A. Emerging concepts in the pathophysiology and treatment of obesity-associated hypertension. Curr Opin Cardiol 2002; 17: 355-359.10.1097/00001573-200207000-0000612151869
]Search in Google Scholar
[
55. Angrisani L, Santonicola A, Iovino P, et al. IFSO Worldwide Survey 2016: Primary, Endoluminal, and Revisional Procedures. Obes Surg 2018;28:3783-94.10.1007/s11695-018-3450-230121858
]Search in Google Scholar
[
56. Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2011. Obes Surg 2013;23:427-36.10.1007/s11695-012-0864-023338049
]Search in Google Scholar
[
57. English WJ, DeMaria EJ, Brethauer SA, et al. American Society for Metabolic and Bariatric Surgery estimation of metabolic and bariatric procedures performed in the United States in 2016. Surg Obes Relat Dis 2018;14:259-63.10.1016/j.soard.2017.12.01329370995
]Search in Google Scholar
[
58. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004;292:1724-37.10.1001/jama.292.14.172415479938
]Search in Google Scholar
[
59. Chang SH, Stoll CR, Song J, et al. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. JAMA Surg 2014;149:275-87.10.1001/jamasurg.2013.3654396251224352617
]Search in Google Scholar
[
60. Gloy VL, Briel M, Bhatt DL, et al. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ 2013;347:f5934.10.1136/bmj.f5934380636424149519
]Search in Google Scholar
[
61. Puzziferri N, Roshek TB, 3rd, Mayo HG, et al. Long-term follow-up after bariatric surgery: a systematic review. JAMA 2014;312:934-42.10.1001/jama.2014.10706440900025182102
]Search in Google Scholar
[
62. Kang JH, Le QA. Effectiveness of bariatric surgical procedures: A systematic review and network meta-analysis of randomized controlled trials. Medicine (Baltimore) 2017; 96:e8632.10.1097/MD.0000000000008632570482929145284
]Search in Google Scholar